StockNews.AI
ORGO
StockNews.AI
4 hrs

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO

1. Pomerantz LLP investigates claims against Organogenesis for potential securities fraud. 2. ORGO's Phase 3 trial of ReNu failed its primary endpoint for pain reduction. 3. Stock price dropped 12.39% following the release of disappointing trial results. 4. The company plans to request a BLA meeting with the FDA by October. 5. Investors may be impacted by potential legal actions regarding corporate misconduct.

5m saved
Insight
Article

FAQ

Why Very Bearish?

The significant stock drop following trial failure suggests deep market concerns. Historical example: similar stock declines followed poor clinical trial results in biotech.

How important is it?

The nature of the legal investigation and trial failure may heavily influence investor confidence.

Why Short Term?

Immediate investor sentiment is affected by trial results, but recovery is possible with positive FDA meeting outcomes.

Related Companies

CELGREGNALNY
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Organogenesis Holdings Inc. ("Organogenesis" or the "Company") (NASDAQ: ORGO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.   The investigation concerns whether Organogenesis and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On September 25, 2025, Organogenesis issued a press release disclosing that a second phase 3 trial of its cryopreserved amniotic suspension allograft ReNu missed its primary endpoint, having failed to achieve a significantly significant change in pain reduction.  The Company said it would ask for a pre-Biologics License Application (BLA) meeting with the U.S. Food and Drug Administration by the end of October to examine a submission pathway, "including using the combined efficacy analysis from both Phase 3 studies to support a BLA approval," according to Chief Operating Officer Patrick Bilbo. On this news, Organogenesis's stock price fell $0.58 per share, or 12.39%, to close at $4.10 per share on September 26, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising.  Prior results do not guarantee similar outcomes.   CONTACT:Danielle PeytonPomerantz LLP[email protected]646-581-9980 ext. 7980 SOURCE Pomerantz LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News